Clinical Trial

To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects

Study acronym: Y-4-LC-03
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
Y-4 is a new fixed-dose combination drug product containing two active ingredients of pregabalin and riluzole. The objective is to assess the effect of food on the pharmacokinetics (PK) of pregabalin and riluzole in healthy adult subjects after a single oral dose of Y-4 tablets.
Trial Details
NCT Number NCT07013773
Lead Sponsor Beijing Tiantan Hospital
Collaborators: Neurodawn Pharmaceutical Co., Ltd.
Conditions Healthy Male and Female Subjects
Enrollment 20 participants
Start Date 2025-05-19
Primary Completion 2025-07 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2025-06-10